The biotech company Enlebex, which is traded in the United States and Israel, is developing treatment against the collapse of the immune system. The company has made headlines after reporting on the development of a drug for severe corona patients and now appears to be closer than ever. The five difficult and critical patients who received the treatment of Analybax were released to their home.
In an interview with BizPortal, Shai Novik, the company’s CEO, he believed it would come. Novik has previously made an exit with Prolor, which sold for half a billion dollars, and intends to do so again, this time for an even bigger approach. (For the full interview)
Three patients in critical condition, and two more in critical condition, were treated at Hadassah Ein Kerem Hospital under a clinical trial of the innovative drug of Enlebex. The patients were discharged home, healthy, and negative for the corona virus, about five days on average after receiving the drug.
Alostra, a drug developed by the hospital in collaboration with Enlebex based on the research of Prof. Dror Mevorach, is intended for the treatment of cases of overactive immune system, “cytokine storm”. The immune system goes into a frenzy due to the presence of the bacterium, and even though the bacterium is no longer in the body, the system continues to rage and attacks vital knights. These complications are the number 3 cause of death in the Western world, after heart and cancer.
Hadassah CEO Prof. Zeev Rothstein said: “Despite the war around and alongside intensive preparations to absorb the growing numbers of critically ill patients, Hadassah continues to innovate and lead the breakthroughs in treating these corona patients and are pleased that a drug developed in research within our hospital walls shows therapeutic potential. In these patients. ”
“We are pleased that the patients in a difficult and critical condition have recovered as a result of the treatment with Allstra.”
Comments on the article(0):
Your response has been received and will be published subject to system policies.
For a new response
Your response was not sent due to a communication problem, please try again.
Return to comment
*The article has been translated based on the content of Source link by https://www.bizportal.co.il/capitalmarket/news/article/784797
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!